3 papers in the library · 49 citations · publishing 2025
J Affect Disord October 10, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. correction
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
The Journal of Clinical Psychiatry March 3, 2025 Guy M. Goodwin, Ania Nowakowska, Merve Atli et al. 14 citations
Background: The largest randomized study of psilocybin to date demonstrated the efficacy of COMP360 25 mg (Compass Pathways' investigational proprietary pharmaceutical-grade synthesized psilocybin formulation) in participants with treatment-resistant depression (COMP 001), compared with 10 mg and 1 mg doses. Here, we report findings from COMP 004, a 52-week observational follow-up of patients...
Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations
To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...